Search

United Therapeutics Corp

Открыт

СекторЗдравоохранение

516.52 -1.53

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

508.46

Макс.

530.88

Ключевые показатели

By Trading Economics

Доход

58M

333M

Продажи

1.8M

783M

P/E

Средняя по отрасли

18.206

57.366

Прибыль на акцию

7.27

Рентабельность продаж

42.512

Сотрудники

1,400

EBITDA

32M

376M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+26.8% upside

Дивиденды

By Acuity

Следующий отчет о доходах

28 окт. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-3.9B

22B

Предыдущая цена открытия

518.05

Предыдущая цена закрытия

516.52

Новостные настроения

By Acuity

31%

69%

99 / 340 Рейтинг в Healthcare

United Therapeutics Corp График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

26 авг. 2026 г., 19:46 UTC

News

United Therapeutics shares are lower as CEO Martine Rothblatt exercised an option for 9,500 shares at $135.42, raising potential supply concerns.

25 авг. 2026 г., 23:26 UTC

United Therapeutics Corp. shares are trading roughly flat in after-market hours, reflecting routine performance and remaining near the middle of their one-month trading range.

24 авг. 2026 г., 21:01 UTC

Event

United Therapeutics shares lower in after-market hours following FDA acceptance of ralinepag's New Drug Application for pulmonary arterial hypertension.

21 авг. 2026 г., 19:46 UTC

News

United Therapeutics Corp shares are lower amid rising U.S. Treasury yields, which have heightened concerns about inflation and government debt levels.

20 авг. 2026 г., 23:16 UTC

Shares of United Therapeutics Corp are trading higher in after-market hours, despite routine fluctuations and a decrease from an earlier high.

19 авг. 2026 г., 22:02 UTC

United Therapeutics Corp. shares declined in after-market trading, reversing gains from the previous three sessions. No specific news was identified to explain the drop.

18 авг. 2026 г., 19:11 UTC

Event
News

United Therapeutics shares are higher, supported by insider activity and full enrollment in the TETON-PPF study evaluating Tyvaso for pulmonary fibrosis.

17 авг. 2026 г., 19:46 UTC

News
Social Media
Event

United Therapeutics Corp completed enrollment in its Phase 3 TETON-PPF study for Tyvaso, and shares are advancing during Monday's session, despite a pullback earlier.

13 авг. 2026 г., 19:51 UTC

United Therapeutics Corp shares are lower today, breaking a trend of higher closes. No specific news was identified to explain the decline.

12 авг. 2026 г., 23:01 UTC

United Therapeutics Corp shares are higher in after-market trading, supported by easing concerns over Federal Reserve rate hikes amid rising consumer prices.

11 авг. 2026 г., 23:02 UTC

United Therapeutics Corp is trading lower in after-market hours, continuing a trend of three consecutive daily declines without any specific news driving the movement.

10 авг. 2026 г., 20:06 UTC

United Therapeutics Corp shares are lower during Monday's session, with no specific news identified to explain the decline amid broader market volatility.

7 авг. 2026 г., 19:51 UTC

Social Media
News

United Therapeutics Corp shares are higher, driven by positive sentiment from significant insider transactions and strong investor interest amid a rising Biotechnology sector.

6 авг. 2026 г., 23:01 UTC

United Therapeutics Corp. shares are higher in after-market trading, continuing a steady increase since Thursday's close and remaining above the 20-day moving average.

5 авг. 2026 г., 20:02 UTC

News
Social Media

United Therapeutics reported second-quarter revenues of $783.3 million, missing estimates of $805.6 million, while EPS of $7.27 exceeded expectations by $0.18.

4 авг. 2026 г., 23:51 UTC

Shares of United Therapeutics Corp. are lower in after-market hours, remaining below the 20-day moving average and near the lower end of their one-month trading range.

3 авг. 2026 г., 19:16 UTC

Shares of United Therapeutics Corp are lower today, trading near the lower end of their one-month range amid a broader market rally in other sectors.

30 июл. 2026 г., 14:36 UTC

Event

United Therapeutics shares are higher following the publication of full ADVANCE OUTCOMES study results in The Lancet, pending FDA approval for ralinepag.

29 июл. 2026 г., 20:51 UTC

Event

United Therapeutics shares are higher in after-market trading following The Lancet's publication of results from the ADVANCE OUTCOMES study on Ralinepag for PAH.

28 июл. 2026 г., 18:21 UTC

United Therapeutics Corp. shares are lower today, continuing a decline since Monday's close amid broader market trends and three consecutive sessions of lower finishes.

24 июл. 2026 г., 16:36 UTC

News
Social Media

United Therapeutics appointed Victor Dzau to its Board of Directors, enhancing its strategic direction. Shares are modestly higher since Thursday's close.

22 июл. 2026 г., 19:41 UTC

News

United Therapeutics filed an $833.4 million shelf registration for 1.5 million shares, contributing to downward pressure on shares amid broader market movements.

21 июл. 2026 г., 16:56 UTC

United Therapeutics Corp is seeing modest gains today, with positive sentiment from Asian markets contributing to overall investor optimism. No specific news was identified.

Сравнение c конкурентами

Изменение цены

United Therapeutics Corp Прогноз

Целевая цена

By TipRanks

26.8% рост

Прогноз на 12 месяцев

Средняя 655.13 USD  26.8%

Максимум 714 USD

Минимум 515 USD

Основано на мнении 9 аналитиков Wall Street, спрогнозировавших целевые цены для United Therapeutics Corp на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

9 ratings

7

Покупка

2

Удержание

0

Продажа

Настроения

By Acuity

99 / 340Рейтинг в Здравоохранение

Новостные настроения

Свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Выше среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
help-icon Live chat